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Abstract. The activated leukocyte cell adhesion molecule
(ALCAM) is involved in cell migration and adhesion.
Decreased levels of ALCAM expression in breast cancer
tissue are known to correlate with poor prognosis. The current
study specifically investigated the ALCAM expression in
tumours which developed skeletal metastasis. Fresh frozen
primary breast cancer tissues (n=234) and non-neoplastic
mammary tissue (n=34) were used. The distribution and
location of ALCAM was assessed using immunohistochemical
methods and the level of ALCAM was determined using
quantitative RT-PCR. The results were analysed against the
clinical and pathological data. ALCAM staining was largely
membranous and cytoplasmic in normal epithelial cells and
is significantly stronger than in cancer cells (p=0.023) and
patients who develop skeletal metastasis (p=0.048). The
ALCAM transcript levels were lowest in patients with skeletal
metastasis (p=0.0048) but were also significantly lower in
patients who developed local recurrence (p=0.040) and in
those who died from breast cancer (p=0.0075). Patients with
moderate and poor prognostic indices have a lower level than
those with a good index (p=0.05 and p=0.0089 respectively)
and ER-positive tumours show a lower level than ER-
negative (p=0.043). Ductal carcinomas, 86% of the cohort,
have a similar pattern of changes with skeletal metastasis
patients having significantly lower levels (p=0.015). This
study has, for the first time, shown that patients who develop
skeletal metastasis tend to have the lowest levels of ALCAM
transcripts in their breast cancers, a finding potentially useful
for clinical practice.
Introduction
The breast is the most frequent site of cancer in women and
ranks second to lung cancer in the number of deaths in
women (1). It is generally accepted that there are a number of
prognostic factors in breast cancer that significantly influence
survival. These include the size of the primary breast tumour,
the histological type, histological grade, presence or absence of
regional/auxillary lymph node metastases, presence or
absence of oestrogen and progesterone receptors and the
presence or absence of distant metastases (2). It has been
reported that the skeleton is one of the most common sites for
distant metastases in breast cancer with the cumulative
incidence at any time being 8.2% at 2 years and 27.3% at
10 years (3). There are classically 5 types of primary cancer
that metastasize to the skeleton of which breast cancer is
responsible for the greatest number [breast 35%, prostate 30%,
bronchus 10%, kidney 5%, thyroid 2% and others 18% (4)].
There is a significantly poorer prognosis if skeletal metastasis
occurs. The aim is to be able to identify which breast cancers
will metastasize so treatment strategies and a more accurate
prognosis can be delivered.
The activated leukocyte cell adhesion molecule (ALCAM)
is a glycoprotein of the immunoglobulin superfamily. ALCAM
has been identified in multiple species and has different
names depending on the species and laboratory that described
it: chicken neural adhesion molecule BEN/SC-1/DM-GRASP
(5,6,7), rat KG-CAM (8), fish neurolin (9), human melanoma
metastasis clone D (MEMD) (10), mouse/human CD166
(11,12), and rat HB2 (13,14). ALCAM has 5 extracellular
immunoglobulin domains (two NH2-terminal, membrane-
distal variable- [V]-type folds and three membrane-proximal
constant- [C2]-type immunoglobulin folds), a transmembrane
region and a short cytoplasmic tail (15).
It was first implicated in cell migration when originally
being mapped (11) and it has since been reported to be
involved in homotypic/homophilic and heterotypic/
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heterophilic (to CD6) adhesion (16). It has been studied in
tumours before: malignant melanoma in which approximately
half were found to have ALCAM positivity and the expression
is seen in the vertical growth phase of melanoma (17) and
prostate cancer in which the ALCAM expression was lost in
high grade tumours (18), colorectal carcinoma (19) and
oesophageal squamous cell carcinoma (20). ALCAM has also
been reported to be involved in capillary tube formation (21)
and in vessel invasion in cartilage in vitro (22).
Degen et al (10) were the first to look for the presence of
ALCAM in breast carcinoma and performed Northern blot
analysis of MEMD (a partner to ALCAM) mRNA and found
expression in the MCF-7 mammary carcinoma cell line. Studies
have more recently demonstrated ALCAM in resected breast
tumours (23) and King et al reported a decreased level of the
ALCAM expression correlating with nodal involvement,
grade, TNM stage, poor prognostic index (NPI) and clinical
outcome (local recurrence and death) (24). These findings have
recently been substantiated by Jezierska et al who similarly
concluded that low ALCAM concentrations correlated with an
aggressive phenotype (25).
Although ALCAM has been identified as being associated
with disease progression, there has been no investigation into
whether the location of metastasis is linked to ALCAM. In the
present study we evaluated the ALCAM expression in breast
carcinoma using tissue from patients who have been followed
for 10 years and have been studied extensively in our
department (24,26,27,28,29,30,31). Owing to the relatively
small numbers of patients developing skeletal metastases we
have increased our numbers by adding a second cohort of
breast cancer patients. Our results suggest that a decreased
ALCAM expression is of clinical significance in skeletal
metastasis from ductal breast cancer.
Materials and methods
Materials. The RNA extraction kit and the RT kit were
obtained from AbGene Ltd. (Surrey, UK). PCR primers were
designed using Beacon Designer (Palo Alto, CA, USA) and
synthesized by Invitrogen Ltd. (Paisley, UK). Molecular
biology-grade agarose and the DNA ladder were from
Invitrogen (Carlsbad, CA, USA). The master mix for routine
PCR and quantitative PCR (Qabsolute) were from AbGene
Ltd. Mouse monoclonal antibody ALCAM/CD166 (for
immunohistochemistry) was obtained from Novocastra
Laboratories (Newcastle upon Tyne, UK). Peroxidase
conjugated anti-mouse antibodies were from Sigma (Poole,
Dorset, UK) and a biotin universal kit was from Dako Ltd.
(Carpinteria, CA, USA).
Cells and tissues. Primary breast cancer tissues (n=234) and
non-neoplastic mammary tissue (from the same mastectomy
specimens) (n=34) were collected with the approval of the
local ethics committees in Cardiff and London and were
stored at -70˚C. Patients were routinely followed clinically
after surgery and their details stored in a database. The
median follow-up period was 120 months. Details of
histology were obtained from pathology reports provided by
an independent specialist pathologist using hematoxylin and
eosin (H&E)-stained frozen sections. The results are shown
in Table I. Where normal non-neoplastic mammary tissues
were used, no tumour cells were found in the sections. The
results of the primary ductal breast cancer tissues (n=190) are
shown in Table I.
Tissue processing, RNA extraction and cDNA synthesis.
Frozen sections of tissue were cut at a thickness of 5-10 μm
and were kept for immunohistochemistry and routine histology.
Other 15-20 μm sections were mixed and homogenized using
a hand-held homogenizer, in ice-cold RNA extraction solution.
The concentration of RNA was determined using a UV
spectrophotometer. Reverse transcription was carried out using
an RT kit with an anchored oligo dT primer supplied by
AbGene and 1 μg total RNA in a 96-well plate. The quality of
cDNA was verified using ß-actin primers (5'-caggaggttgaa
ggactaaa-3' and 5'-gggatcagttttctttgtca-3').
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Table I. Clinical and pathological information of the study cohort.
–––––––––––––––––––––––––––––––––––––––––––––––––
Clinical information Entire Ductal
cohort cancers
–––––––––––––––––––––––––––––––––––––––––––––––––
Nodal status
Negative 107 87
Positive 105 102
Grade
Grade 1 35 24
Grade 2 78 57
Grade 3 108 105
Histology
Ductal 190 N/A
Lobular 11 N/A
Medullary 1 N/A
Tubular 2 N/A
Mucinous 14 N/A
Other 2 N/A
NPI staging
NPI 1 74 55
NPI 2 89 77
NPI 3 40 36
ER status
Negative 107 90
Positive 105 89
Bone metastasis
Negative 222 173
Positive 12 9
Clinical outcome
Disease-free 159 127
Metastasis 21 20
Local recurrence 6 5
Died of breast cancer 29 23
Died of unrelated disease 7 7
–––––––––––––––––––––––––––––––––––––––––––––––––
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Quantitative analysis of ALCAM transcript and protein. The
level of ALCAM transcripts from the earlier prepared cDNA
was determined using a real-time quantitative PCR, based on
the Amplifluor™ technology (32), modified from a previously
reported method (33). Briefly, pairs of PCR primers were
similarly designed using the Beacon Designer software
(version 2) (5'-caggaggttgaaggactaaa-3' and 5'-gggatcag
ttttctttgtca-3'), but an additional sequence, known as the Z
sequence (5'-actgaacctgaccgtaca-3'), which is complementary
to the universal Z probe (30) (Intergen Inc., Livingston, UK),
was added to one of the primers (ALCAMZr). A Taqman
detection kit for ß-actin was purchased from Perkin-Elmer
(Surrey, UK). The reaction was carried out using the following:
Hot-start Q-master mix (Abgene), 10 pmol specific forward
primer, 1 pmol reverse primer that had the Z sequence, 10 pmol
FAM-tagged probe (Intergen Inc.) and cDNA from ~50 ng
RNA. The reaction was carried out using IcyclerIQ™ (Bio-
Rad, Hemel Hempstead, UK), which is equipped with an
optic unit that allows real-time detection of 96 reactions, using
the following conditions: 94˚C for 8 min, then 38 cycles of
94˚C for 15 sec, 55˚C for 20 sec, 72˚C for 40 sec and finally
72˚C for 10 min. The levels of the transcripts were generated
from a standard [purified plasmid with known quantity (34)]
that was simultaneously amplified with the samples and which
are presented as relative levels calculated from the internal
standard. The epithelial content within the tumours was taken
into account by normalizing ALCAM against cytokeratin 19.
The cytokeratin 19 forward and reverse primers were 5'-
caggtccgaggttactgac-3' and 5'-actgaacctgaccgtacacac
tttctgccagtgtgtcttc-3', respectively.
Immunohistochemical staining. The procedure was similar to
that previously reported, with minor modifications (26,28).
Briefly, the frozen sections of breast tumour and non-
neoplastic breast tissue were cut at a thickness of 5 μm using
a cryostat. The sections were mounted on microscope slides,
air-dried and then fixed in a mixture of 50% acetone and
50% methanol for 20 min. The sections were then placed in a
‘Menapath’ autowash buffer for 5-10 min to rehydrate.
Sections were incubated for 20 min in a horse serum blocking
solution and probed with the primary antibody (1:50 dilution
ALCAM) at room temperature for 1 h. Following extensive
washings, sections were incubated for 30 min in the secondary
horse serum. Following washings, Avidin biotin complex
(Vector Laboratories Ltd.) was then applied to the sections,
followed by extensive washings. Diaminobenzidine
chromogen (Vector Laboratories Ltd.) was then added to the
sections, which were incubated in the dark for 5 min. The
sections were then dehydrated in ascending grades of
methanol before clearing in xylene and mounting under a
coverslip before initial photographs were taken. A rehydration
process was then performed with descending grades of
methanol before removing the coverslip and counterstaining
in Mayer's hematoxylin for 1 min. The process of dehydration
and mounting was then repeated.
Staining intensity was semiquantified using a method
established in our laboratory (35), which was modified and
based on that reported by Fidler and colleagues (36). Briefly,
gray-scale digitized images were imported into the Optimas
software (Optimas 6.0, Optimus Corp., Bothell, WA, USA).
The intensity of the cell adhesion molecules was measured in
two locations from randomly chosen cells: the cytoplasmic
and the intercellular adhesion regions, where appropriate.
Control staining (without primary antibody) was used for the
extraction of the background staining. Intensity data were
exported to Excel for statistical analysis and are presented
here as the mean intensity of either the cytoplasmic region or
membranous staining.
Statistical analysis. A statistical analysis of RNA transcript data
was carried out using the Mann-Whitney U test. Furthermore,
a statistical analysis of the immunohistochemical staining
was carried out using the two-sided two-tailed t-test.
Results
Immunohistochemical staining. ALCAM staining was seen in
normal epithelial cells of normal breast tissue and cancer cells
in tissue in patients who went onto develop skeletal metastasis
(Fig. 1A, B and C). Analysis of the staining intensity (Fig. 1D)
shows that the cytoplasmic staining in normal breast tissue is
significantly stronger than that in either the standard breast
cancer tissue (p=0.023) or the breast cancer tissue from patients
who went onto develop skeletal metastasis (p=0.048).
ALCAM expression in breast cancer and normal tissue. Fig. 2A
shows that the number of ALCAM transcripts in breast cancer
is lower than in the normal breast tissue. The results are not,
however, statistically significant (p=0.78). It would be expected
that the levels would have been significantly lower and a
possible reason for the disparity may be that there is a
difference in cellularity between breast tumour tissues and
the normal breast tissues.
ALCAM expression in the cohort of breast cancer patients. It
was previously reported by King et al (24) on a smaller cohort,
that there were significantly lower levels of ALCAM
transcripts in more aggressive tumours. In the larger cohort
we found a similar pattern with significantly lower levels of
ALCAM found in patients with a widely recognized indicator
of poor prognosis: with metastasis, with recurrence and bone
metastasis, poor prognostic index (NPI) and positive ER
status. These results are shown in Figs. 2B, 3A and 4A.
The most noteworthy of the results above is the difference
in the ALCAM transcript level for the different patient
clinical outcomes which were identified during their follow-up.
Fig. 2B shows lower transcript levels in the patients with
complications of metastasis, local recurrence (p=0.040),
skeletal metastasis (p=0.0048) and death (p=0.0075).
Looking specifically at the patients who went on to develop
skeletal metastasis, we can see that these patients have the
lowest levels of ALCAM of any of the patient groups.
Although not statistically lower than the other complications
of breast cancer (other metastases, local recurrence and death)
it is the most statistically different from the patients who were
disease-free (p=0.0048).
Figs. 3A and 4A show the differences in transcript levels
when comparing patients with moderate and poor NPI
prognosis to those with a good prognosis (p=0.05 and
p=0.0089 respectively) and those with a positive ER status
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(p=0.043). Fig. 5A shows the difference in ALCAM transcript
levels in patients with and without nodal involvement and
although not significant, it does suggest a lower level in the
node-positive patients (p=0.16).
ALCAM expression in ductal carcinoma. When subdividing the
cancer groups the ductal carcinomas were the overwhelming
subgroup (86%). We have therefore re-analyzed the data and
found the same pattern of differences. Again there is a
significant difference in the ALCAM transcript level in each
of the different clinical outcome settings (Fig. 2C). For local
recurrence (p=0.0035), skeletal metastasis (p=0.015) and
death (p=0.024) the transcript levels are less than the levels
found in patients with no recurrence.
Figs. 3B, 4B and 5B show the results of patients with: a
poor NPI prognosis to those with a good prognosis (p=0.021),
patients with a positive ER status to a negative status
(p=0.05) and, although not significant, the trend that patients
with a positive nodal status tend to have lower ALCAM
transcript levels than patients with no positive nodes.
Although not looked at directly in this study it was notable
that patients with an ER negative status who went on to develop
skeletal metastasis had a significantly lower level (p=0.0061)
of ALCAM transcript than those who did not develop skeletal
metastasis.
Discussion
It has previously been demonstrated that decreased ALCAM
transcripts in the primary tumours correlated with nodal
involvement, higher grade tumours, higher TNM stage, worse
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Figure 1. Immunohistochemical staining showing (A) normal tissue, (B) tissue from breast cancer patient (black arrows indicate cancer cells and white arrows
indicate residue of normal tissue with staining at the intracellular junction), (C) tissue from breast cancer patient with skeletal metastasis and (D) analysis of
staining intensity, shown at x100 magnification and x400 for the inserts.
Figure 2. ALCAM transcript levels for the different patient clinical outcome
groups (A) compared to normal patients, (B) disease-free patients and (C) in
ductal carcinoma compared to disease-free patients.
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NPI index, presence of local recurrence and death due to
breast cancer (24). These data suggested that a decreased
ALCAM expression in the primary tumour was of clinical
significance and that a reduced expression indicates a more
aggressive phenotype and poor prognosis. In this analysis we
used an expanded tumour cohort of 234 breast cancer patients
to re-evaluate the previous findings and for the first time,
specifically identified patients who went on to develop skeletal
metastasis.
Normal ductal epithelial cells in breast tissue showed
positivity to ALCAM in immunohistochemical stains (Fig. 1A,
B and C). This positivity was also seen in breast cancer tissue
and in breast cancer tissue from patients who went on to
develop skeletal metastasis. The level of staining was, however,
significantly lower in the breast cancer tissues than that of
normal ductal epithelial cells (Fig. 1D). Immunohistochemical
staining of breast tissues alone with the antibody used would
therefore not distinguish between benign and malignant cells
using the method described in this study. Burkhardt and
colleagues, however, found that there was a higher ALCAM
expression in intraductal and invasive breast carcinomas than
in normal breast tissue. They used the same antibody as used
in this study, but at a different concentration and with a slightly
different method (37). The established pathologic criteria for
carcinoma, including the architecture, nuclear pleomorphism
and mitotic counts, therefore have to be evaluated.
The level of ALCAM transcripts is lower in primary
tumours compared to normal breast tissue from the same
mastectomy specimens, although it was not statistically
significant (Fig. 2A). This correlates well with the immuno-
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Figure 4. ALCAM transcript levels in prognostic groups defined by their
oestrogen receptor (ER) status, (A) entire cohort and (B) ductal carcinomas.
Figure 5. ALCAM transcript levels in prognostic groups defined by their
nodal involvement, (A) entire cohort and (B) ductal carcinomas.
Figure 3. ALCAM transcript levels in prognostic groups defined by their
NPI, (A) entire cohort and (B) ductal carcinomas.
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histochemical staining results, in that individual tumour cells
stained more weakly than individual normal mammary
epithelial cells (Fig. 1A, B and C). However, we would have
expected a much lower result. There are a number of possible
reasons for this discrepancy. There may be a difference in
cellularity between breast tumour tissues and the normal
breast tissues thereby giving an inappropriately raised
transcript level in the breast tumours. The error may rest with
a different epithelial/tumour cell content in different tumours
and the possible contribution from infiltrating immune cells
since haemopoietic stem cells and activated T lymphocytes
express ALCAM (38-41). The cohort of normal breast tissue
is also relatively small (n=34) compared to the number in the
breast cancer cohort (n=234) thereby increasing the risk of
statistical error.
The patients who went on to develop skeletal metastasis
tended to have the lowest levels of ALCAM transcript out of
all the different patient groups, lower even than those that died
from the original breast cancer (Fig. 2B). When compared to
the patients who were disease-free at follow-up, the ALCAM
transcript levels were significantly lower (p=0.0048). The
results were reproduced when looking at the sub-group of
ductal carcinomas (Fig. 2C) with the ALCAM transcript level
again being significantly lower (p=0.015).
The results gathered from this enlarged cohort confirmed
the previous finding by King et al (25). It can be seen that there
are lower levels of ALCAM transcripts in the patients who
went on to develop metastasis and the level was statistically
lower in patients with local recurrence (p=0.0040) or who
died from the disease (p=0.0075) (Fig. 2B).
The NPI (42) is a clinical parameter of prognosis which
combines tumour size, lymph node stage and histological
grade into a formula to determine prognostic groups. The
group with NPI<3.4 has the best prognosis, NPI>5.4 is
associated with poor prognosis and NPI=3.4-5.4 has an
intermediate prognosis. The scoring system has been validated
in prospective studies (43) and is used in countries such as
the UK (44). We demonstrated that patients with a moderate
and poor prognosis have a significantly lower ALCAM
transcript level than those patients with a good prognosis
(moderate p=0.05 and poor p=0.0089).
A positive ER status for a patient is another widely
recognized indicator of a poor prognosis and the ALCAM
transcript levels were lower (p=0.043) in the positive group
compared to the ER negative group. Although not statistically
significant, the ALCAM level was lower in patients who
were found to have a positive lymph node status (p=0.16).
This study also looked at the dominant cancer type sub-
group of ductal carcinomas. Ductal cancers make up 86% of
the entire cohort and the same pattern of lower ALCAM
transcript levels in the patients with poor prognostic indicators
was seen as it was in the cohort as a whole. There was a
significantly lower level of ALCAM transcripts in the
patients with a poor NPI prognosis compared to those with a
good prognosis (p=0.021), lower levels in ER-positive
patients (p=0.05) and lower levels in node-positive patients
(p=0.33).
We hypothesize that the reduced expression of ALCAM,
a molecule involved in cell adhesion, may allow the tumour
cells to disaggregate and so enter the circulation and
metastasize. This property was seen in other cell adhesion
molecules such as E-cadherin (45-47). E-cadherin was
demonstrated as having the ability to shed its cadherin
extracellular domain, to move from the cell surface to the
cytoplasm or from the cell-cell adhesion areas to other areas
of the membrane and transcriptional abnormalities as a result
of gene promoter hypermethylation (48). ALCAM was
reported to co-localize with E-cadherin in epithelial cells (49)
and it may have similar abilities.
In conclusion, ALCAM is a glycoprotein that is involved
with cellular adhesion, proliferation and tumour progression.
In breast carcinoma, decreased ALCAM transcripts in the
primary tumours are synonymous with predictors of poor
prognosis: higher TNM stage, worse NPI index, nodal
involvement, the presence of local recurrence and death due to
breast cancer. This study has for the first time demonstrated
that the patients with the lowest levels of ALCAM transcripts
have a possibility of developing skeletal metastasis. This
study suggested that the level of the ALCAM expression in
primary breast carcinoma has clinical significance and that a
reduced expression indicates a more aggressive phenotype
and poor prognosis. This fact could be used to provide patients
with a more accurate prognosis and identify those who may
benefit from enhanced monitoring and early medical and
orthopaedic treatment.
Acknowledgements
The authors would like to thank Cancer Research Wales and
Breast Cancer Hope Foundation for supporting this work.
References
1. American Cancer Society: Cancer Facts and Figures 2006.
Atlanta, GA, 2006.
2. Fleming I, Cooper J, Henson D, Hutter R, Kennedy B, Murphy G,
O'Sullivan B, Sobin L and Yarbro J: Breast. In: AJCC Cancer
Staging Manual. 5th edition Lippincott-Raven, Philadelphia,
pp171-178, 1997.
3. Colleoni M, O’Neill A, Goldhirsch A, Gelber RD, Bonetti M,
Thürlimann B, Price KN, Castiglione-Gertsch M, Coates AS,
Lindtner J, Collins J, Senn H-J, Cavalli F, Forbes J, Gudgeon A,
Simoncini E, Cortes-Funes H, Veronesi A, Fey M and
Rudenstam C-M: Identifying breast cancer patients at high risk
for bone metastases. J Clin Oncol 18: 3925-3935, 2000.
4. Downey SE and Bundred NJ: Bone Metastases. In: Recent
Advances in Surgery 19. 1st edition, Johnson CD (ed).
Churchill Livingstone, Edinburgh, pp109-128, 1996.
5. Pourquie O, Corbel C, Le Caer J-P, Rossier J and Le Douarin N:
BEN: a surface glycoprotein of the immunoglobulin superfamily,
is expressed in a variety of developing systems. Proc Natl Acad
Sci USA 89: 5261-5265, 1992.
6. Tanaka H, Matsui T, Agata A, Tomura M, Kubota I,
McFarland KC, Kohr B, Lee A, Phillips HS and Shelton DL:
Molecular cloning and expression of a novel adhesion molecule,
SC1. Neuron 7: 535-545, 1991.
7. Burns F, von Kannen S, Guy L, Raper J, Kamholz J and Chang S:
DM-GRASP, a novel immunoglobulin superfamily axonal surface
protein that supports neurite extension. Neuron 7: 209-220, 1991.
8. Peduzzi J, Irwin M and Geisert E: Distribution and characteristics
of a 90 kDa protein, KG-CAM in the rat CNS. Brain Res 640:
296-307, 1994.
9. Paschke K, Lottspeich F and Stuermer C: Neurolin, a cell surface
glycoprotein on growing retinal axons in the goldfish visual
systems, is re-expressed during retinal axonal regeneration. J
Cell Biol 117: 863-875, 1992.
10. Degen W, van Kempen L, Gijzen E, van Groningen J, van Kooyk Y,
Bloemers H and Swart GWM: MEMD, a new cell adhesion
molecule in metastasizing human melanoma cell lines, is
identical to ALCAM (activated leukocyte cell adhesion
molecule). Am J Pathol 152: 805-813, 1998.
DAVIES et al:  ALCAM IN BREAST CANCER PATIENTS560
555-561  9/1/08  14:52  Page 560
11. Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang W-C,
Marquardt H, Neubauer M, Pesando JM, Francke U, Haynes BF
and Aruffo A: Cloning, mapping and characterization of
activated leukocyte-cell adhesion molecule (ALCAM), a CD6
ligand. J Exp Med 181: 2213-2220, 1995.
12. Bowen MA, Bajorath J, D'Egidio M, Whitney GS, Palmer D,
Kobarg J, Starling GC, Siadak AW and Aruffo A: Character-
ization of mouse ALCAM (CD166): the CD6-binding domain is
conserved in different homologs and mediates cross-species
binding. Eur J Immunol 27: 1469-1478, 1997.
13. Kurata H, Matsumoto A, Fujiwara Y, Kondo K, Itakura H,
Mitchell A and Fidge N: A candidate high-density lipoprotein
(HDL) receptor, HB2, with possible multiple functions shows
sequence homology with adhesion molecules. J Atheroscler
Thromb 4: 112-117, 1998.
14. Matsumoto A, Mitchell A, Kurata H, Pyle L, Kondo K, Itakura H
and Fidge N: Cloning and characterization of HB2, a candidate
high-density lipoprotein receptor. Sequence homology with
members of the immunoglobulin superfamily of membrane
proteins. J Biol Chem 272: 16778-16782, 1997.
15. Swart GWM: Activated leukocyte cell adhesion molecule (CD
166/ALCAM): developmental and mechanistic aspects of cell
clustering and cell migration. Eur J Cell Biol 81: 313-321 2002.
16. van Kempen LC, Nelissen JMDT, Degen WGJ, Torensma R,
Weidle UH, Bloemers HPJ, Figdor CF and Swart GWM:
Molecular basis for the homophilic activated leukocyte cell
adhesion molecule (ALCAM)–ALCAM interaction. J Biol
Chem 276: 25783-25790, 2001.
17. van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJ,
Garbe C, Weidle UH, Van Muijen GN, Herlyn M, Bloemers HP
and Swart GWM: Truncation of activated leukocyte cell
adhesion molecule: a gateway to melanoma metastasis. J Invest
Dermatol 122: 1293-1301, 2004.
18. Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L,
Loy V, Loening S, Dietel M and Rosenthal A: ALCAM/CD166
is up-regulated in low-grade prostate cancer and progressively
lost in high-grade lesions. Prostate 54: 34-43, 2003.
19. Weichert W, Knosel T, Bellach J, Dieal M and Kistianse G:
ALCAM/CD166 is overexpressed in colorectal carcinoma and
correlates with shortened patient survival. J Clin Pathol
1160-1164, 2004.
20. Verma A, Shukla NK, Deo SVS, Gupta SD and Ralham R:
MEMD/ALCAM: A potential marker for tumour invasion and
nodal metastasis in esophageal squamous cell carcinoma.
Oncology 68: 463-470, 2005.
21. Ohneda O, Ohneda K, Arai F, Lee J, Miyamoto T, Fukushima Y,
Dowbenko D, Lasky LA and Suda T: ALCAM (CD166): its role
in hematopoietic and endothelial development. Blood 98:
2134-2142, 2001.
22. Arai F, Ohneda O, Miyamoto T, Zhang X and Suda T:
Mesenchymal stem cells in perichondrium express activated
leukocyte cell adhesion molecule and participate in bone
marrow formation. J Exp Med 195: 1549-1563, 2002.
23. King JA, Al-Mehdi A-B, Ofori-Acquah SF and Stevens T: Role
of ALCAM in interaction of breast cancer metastases and the
endothelium of the lung. FASEB J 18: 330, 2004.
24. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O
and Jiang WG: Activated leukocyte cell adhesion molecule in
breast cancer: prognostic indicator. Breast Cancer Res 6:
R478-R487, 2004.
25. Jezierska A, Olszewski WP, Pietruszkiewicz J, Olszewski W,
Matysiak W and Motyl T: Activated leukocyte cell adhesion
molecule (ALCAM) is associated with suppression of breast
cancer cells invasion. Med Sci Monit 12: BR245-BR256, 2006.
26. Jiang WG, Douglas-Jones A and Mansel RE: Level of
expression of lipoxygenases and cyclooxygenase-2 in human
breast cancer. Prostaglandins Leukot Essent Fatty Acids 69:
275-281, 2003.
27. Jiang WG, Douglas-Jones A and Mansel RE: Expression of
peroxisome-proliferator activated receptor-gamma (PPARγ) and
the PPARgamma co-activator, PGC-1 in human breast cancer
correlates with clinical outcomes. Int J Cancer 106: 752-757,
2003.
28. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A,
Mokbel K and Mansel RE: Prognostic value of Rho GTPases and
Rho guanine nucleotide dissociation inhibitors in human breast
cancers. Clin Cancer Res 9: 6432-6440, 2003.
29. Parr C, Watkins G, Mansel RE and Jiang WG: The hepatocyte
growth factor regulatory factors in human breast cancer. Clin
Cancer Res 10: 202-211, 2004.
30. Al-Rawi MA, Rmali K, Watkins G, Mansel RE and Jiang WG:
Aberrant expression of interleukin-7 (IL-7) and its signaling
complex in human breast cancer. Eur J Cancer 40: 494-502,
2004.
31. Davies G, Cunnick GH, Mansel RE, Mason MD and Jiang WG:
Levels of expression of endothelial markers specific to tumour-
associated endothelial cells and their correlation with prognosis
in patients with breast cancer. Clin Exp Metastasis 21: 31-37,
2004.
32. Nazarenko IA, Bhatnagar SK and Hohman RJ: A closed tube
format for amplification and detection of DNA based on energy
transfer. Nucleic Acids Res 25: 2516-2521, 1997.
33. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE and
Somlyo AP: Rho-kinase inhibitor retards migration and in vivo
dissemination of human prostate cancer cells. Biochem Biophys
Res Commun 269: 652-659, 2000.
34. Cunnick GH, Jiang WG, Gomez KF and Mansel RE:
Lymphangiogenesis quantification using quantitative PCR and
breast cancer as a model. Biochem Biophys Res Commun 288:
1043-1046, 2001.
35. Davies G, Jiang WG and Mason MD: Cell-cell adhesion
molecules and signaling intermediates and their role in the
invasive potential of prostate cancer cells. J Urol 163: 985-992,
2000.
36. Kuniyasu H, Ellis LM, Evans DB, Abbruzzese JL, Fenoglio CJ,
Bucana CD, Cleary KR, Tahara E and Fidler IJ: Relative
expression of E-cadherin and type IV collagenase genes predicts
disease outcome in patients with resectable pancreatic carcinoma.
Clin Cancer Res 5: 25-33, 1999.
37. Burkhardt M, Mayordomo E, Winzer K-J, Fritzsche F,
Gansukh T, Pahl S, Weichert W, Denkert C, Guski H, Dietel M
and Kristiansen G: Cytoplasmic overexpression of ALCAM is
prognostic of disease progression in breast cancer. J Clin Pathol
59: 403-409, 2006.
38. Uchida N, Yang Z, Combs J, Pourquie O, Nguyen M,
Ramanathan R, Fu J, Welply A, Chen S, Weddell G, Sharma AK,
Leiby KR, Karagogeos D, Hill B, Humeau L, Stallcup WB,
Hoffman R, Tsukamoto AS, Gearing DP and Peault B: The
characterization, molecule cloning, and expression of a novel
hematopoietic cell antigen from CD34+ human bone marrow
cells. Blood 89: 2706-2716, 1997.
39. Stephan J-P, Bald L, Roberts PE, Lee J, Gu Q and Mather JP:
Distribution and function of the adhesion molecule BEN during
rat development. Dev Biol 212: 264-277, 1999.
40. Corbel C, Bluestein HG, Pourquie O, Vaigot P`and Le Douarin NM:
An antigen expressed by avian neuronal cells is also expressed
by activated T lymphocytes. Cell Immunol 141: 99-110, 1992.
41. Corbel C, Pourquie O, Cormier F, Vaigot P and Le Douarin NM:
BEN/SC1/DM-GRASP, a homophilic adhesion molecule, is
required for in vitro myeloid colony formation by avian
hemopoietic progenitors. Proc Natl Acad Sci USA 93: 2844-2849,
1996.
42. Ellis I, Pinder S, Lee A and Elston C: Tumours of the Breast. In:
Diagnostic Histopathology of Tumours. 2nd edition, Fletcher C
(ed). Churchill Livingstone, New York, pp865-930, 2000.
43. Galea MH, Blamey RW, Elston CE and Ellis IO: The Nottingham
prognostic index in primary breast cancer. Breast Cancer Res
Treat 22: 207-219, 1992.
44. Miller W, Ellis I, Sainsbury J and Dixon J: ABC of breast
diseases. Prognostic factors. Br J Med 309: 1573-1576, 1994.
45. Moll R, Mitze M, Frixen UH and Birchmeier W: Differential loss
of E-cadherin expression in infiltrating ductal and lobular breast
carcinomas. Am J Pathol 143: 1731-1742, 1993.
46. Goldstein NS, Bassi D, Watts JC, Layfield LJ, Yaziji H and
Gown AM: E-cadherin reactivity of 95 noninvasive ductal and
lobular lesions of the breast. Implications for the interpretation
of problematic lesions. Am J Clin Pathol 115: 534-542, 2001.
47. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA and Zhang PJ:
Differential expression of E-cadherin in lobular and ductal
neoplasms of the breast and its biologic and diagnostic
implications. Am J Clin Pathol 115: 85-98, 2001.
48. Jiang WG: E-cadherin and its associated protein catenins,
cancer invasion and metastasis. Br J Surg 83: 437-446, 1996.
49. Tomita K, van Bokhoven A, Jansen CFJ, Bussemakers MJG
and Schalken JA: Coordinate recruitment of E-cadherin and
ALCAM to cell-cell contacts by a-catenin. Biochem Biophys
Res Commun 267: 870-874, 2000.
ONCOLOGY REPORTS  19:  555-561,  2008 561
555-561  9/1/08  14:52  Page 561
